The clinical characteristics and prognostic significance of AID, miR-181b, and miR-155 expression in adult patients with de novo B-cell acute lymphoblastic leukemia

References

• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955.
   PubMed Web of Science ®Google Scholar
• Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21–29.
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell.2000;102:553–563.
   PubMed Web of Science ®Google Scholar
• Maizels N. Immunoglobulin gene diversification. Annu Rev Genet. 2005;39:23–46.
   PubMed Web of Science ®Google Scholar
• Hardianti MS, Tatsumi E, Syampurnawati M, et al. Expression of activation-induced cytidine deaminase (AID) in Burkitt lymphoma cells: rare AID-negative cell lines with the unmutated rearranged VH gene. Leuk Lymphoma. 2004;45:155–160.
   PubMed Web of Science ®Google Scholar
• Kuehl WM. Modeling multiple myeloma by AID-dependent conditional activation of MYC. Cancer Cell. 2008;13:85–87.
   PubMed Web of Science ®Google Scholar
• Aguilera NS, Auerbach A, Barekman CL, et al. Activation-induced cytidine deaminase expression in diffuse large B-cell lymphoma with a paracortical growth pattern: a lymphoma of possible interfollicular large B-cell origin. Arch Pathol Lab Med. 2010;134:449–456.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Klemm L, Park E, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015;16:766–774.
   PubMed Web of Science ®Google Scholar
• Zhu X, You Y, Li Q, et al. BCR-ABL1-positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia. Leukemia.2014;28:1666–1675.
   PubMed Web of Science ®Google Scholar
• Gruber TA, Chang MS, Sposto R, et al. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010;70:7411–7420.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13:358–369.
   PubMed Web of Science ®Google Scholar
• de Yebenes VG, Belver L, Pisano DG, et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 2008;205:2199–2206.
   PubMed Web of Science ®Google Scholar
• Borchert GM, Holton NW, Larson ED. Repression of human activation induced cytidine deaminase by miR-93 and miR-155. Bmc Cancer. 2011;11:9.
   PubMed Web of Science ®Google Scholar
• Marques SC, Laursen MB, Bodker JS, et al. MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. Oncotarget. 2015;6:7–25.
   PubMed Web of Science ®Google Scholar
• Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–86.
   PubMed Web of Science ®Google Scholar
• Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005;102:3627–3632.
   PubMed Web of Science ®Google Scholar
• Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–249.
   PubMed Web of Science ®Google Scholar
• Song SJ, Pandolfi PP. MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol. 2014;21:276–282.
   PubMed Web of Science ®Google Scholar
• Persengiev SP. miRNAs at the crossroad between hematopoietic malignancies and autoimmune pathogenesis. Discov Med 2012;13:211–221.
   PubMed Web of Science ®Google Scholar
• Xu LH, Guo Y, Cen JN, et al. Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2015;19:4841–4850.
   PubMed Web of Science ®Google Scholar
• Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34:3226–3239.
   PubMed Web of Science ®Google Scholar
• Duyu M, Durmaz B, Gunduz C, et al. Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. Biomed Res Int. 2014;2014:967585.
   PubMed Web of Science ®Google Scholar
• Zanette DL, Rivadavia F, Molfetta GA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007;40:1435–1440.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Brown PA, Aoun P, et al. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015;13:1240–1279.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Gu W, Chen Z, Hu S, et al. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica. 2005;90:403–405.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764.
   PubMed Web of Science ®Google Scholar
• Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105:3434–3441.
   PubMed Web of Science ®Google Scholar
• Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91:1645–1666.
   PubMed Web of Science ®Google Scholar
• Feldhahn N, Henke N, Melchior K, et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007;204:1157–1166.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia. 2010;24:66–73.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhao X, Durkin L, Rogers HJ, Hsi ED. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia. Hum Pathol 2016;52:173–178.
   PubMed Web of Science ®Google Scholar
• Patten PE, Chu CC, Albesiano E, et al. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood. 2012;120:4802–4811.
   PubMed Web of Science ®Google Scholar
• Lin S, Pan L, Guo S, et al. Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis. PLoS One. 2013;8:e59532.
   PubMed Web of Science ®Google Scholar
• Li ZJ, Huang H, Li YY, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119:2314–2324.
   PubMed Web of Science ®Google Scholar
• Visone R, Veronese A, Balatti V, et al. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget. 2012;3:195–202.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122:1891–1899.
   PubMed Web of Science ®Google Scholar
• Ishihara K, Sasaki D, Tsuruda K, et al. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol. 2012;36:560–565.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry KS, Metzeler KH, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31:2086–2093.
   PubMed Web of Science ®Google Scholar
• Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17:1301–1312.
   PubMed Web of Science ®Google Scholar
• Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9:1–17.
   PubMedGoogle Scholar